At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial
In Brief
A clinical study evaluating Magnesium chloride, Vitamin D, and 1 other intervention for Post-COVID-19 Syndrome and 3 related conditions. Completed, enrolled 150 participants across 1 site.
Detailed Summary
The goal of this double-blind randomized controlled clinical trial is to determine the efficacy of the administration of magnesium chloride + vitamin D as an adjuvant in the treatment of post-Coronavirus Disease (COVID) syndrome. The participants will be integrated: a) Intervention group that will receive 1 g of magnesium chloride (equivalent to 300 mg of elemental magnesium) + 4000 IU of vitamin D once a day, for four months. b) Control group that will receive inert placebo for four months. The outcome variable will be the improvement of the post-COVID syndrome. At the beginning and end of the study, blood samples will be taken to determine serum levels of vitamin D, total magnesium, ionic magnesium, calcium, fasting glucose and lipid profile. The evaluation of the efficacy and safety of the proposed intervention will be carried out by establishing the differences between the intervention and control groups.
Study Details
Timeline
Interventions
Each 650 mg capsule contains 340 mg of magnesium chloride, which must be ingested twice a day with aliments.
Each tablet contains 4000 IU of vitamin D, and must be ingested a pill per night.
Instead of dietary supplements, sodium bicarbonate as inert placebo will be administered twice a day in 650 mg capsules.